{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Suresh S"],"funding":["Intramural NIH HHS","National Institutes of Health"],"pagination":["11685-11697"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8911387"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(9)"],"pubmed_abstract":["Erythropoietin (EPO) regulates erythropoiesis by binding to erythropoietin receptor (Epor) on erythroid progenitor cells. Epor is also expressed on bone forming osteoblasts and bone loss accompanies EPO-stimulated erythropoiesis in mice. Mice with Epor restricted to erythroid tissue exhibit reduced bone and increased marrow adipocytes; in contrast, transgenic mice (Tg) with osteoblastic-specific deletion of Epor exhibit reduced trabecular bone with age without change in marrow adipocytes. By 12 weeks, male Tg mice had 22.2% and female Tg mice had 29.6% reduced trabecular bone volume (BV) compared to controls. EPO administration (1200 U/kg) for 10 days reduced trabecular bone in control mice but not in Tg mice. There were no differences in numbers of osteoblasts, osteoclasts, and marrow adi"],"journal":["FASEB journal : official publication of the Federation of American Societies for Experimental Biology"],"pubmed_title":["Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis."],"pmcid":["PMC8911387"],"funding_grant_id":["ZIA DK025061"],"pubmed_authors":["Noguchi CT","Suresh S","Lee J"],"additional_accession":[]},"is_claimable":false,"name":"Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis.","description":"Erythropoietin (EPO) regulates erythropoiesis by binding to erythropoietin receptor (Epor) on erythroid progenitor cells. Epor is also expressed on bone forming osteoblasts and bone loss accompanies EPO-stimulated erythropoiesis in mice. Mice with Epor restricted to erythroid tissue exhibit reduced bone and increased marrow adipocytes; in contrast, transgenic mice (Tg) with osteoblastic-specific deletion of Epor exhibit reduced trabecular bone with age without change in marrow adipocytes. By 12 weeks, male Tg mice had 22.2% and female Tg mice had 29.6% reduced trabecular bone volume (BV) compared to controls. EPO administration (1200 U/kg) for 10 days reduced trabecular bone in control mice but not in Tg mice. There were no differences in numbers of osteoblasts, osteoclasts, and marrow adi","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2025-04-19T12:56:38.453Z","creation":"2025-04-19T12:56:38.453Z"},"accession":"S-EPMC8911387","cross_references":{"pubmed":["32671900"],"doi":["10.1096/fj.202000888R","10.1096/fj.202000888r"]}}